Category: Clinical Trials

EuroPCR: 1-year results continue to support Edwards' next-gen Sapien XT valve

May 22, 2013 by Arezu Sarvestani

Edwards Lifesciences' original Sapien (left) and new Sapien XT (right) valves.

EuroPCR: Boston Scientific's Lotus TAVI bests rivals with less leakage

May 22, 2013 by Arezu Sarvestani

Massachusetts-based medical device titan Boston Scientific (NYSE:BSX) released early data from a study of its Lotus transcatheter aortic valve implantation system, highlighting very low rates of paravalvular leakage that analysts said could give the company some leverage in the highly charged TAVI market.

Covidien touts positive study data from Barrx ablation system

May 22, 2013 by Sony Salzman

Covidien (NYSE:COV) touted study results showing that the Barrett's esophagus treatment it acquired along with Barrx 2 years ago reduces pre-cancerous tissue.

EuroPCR: Medtronic's CoreValve is a cost-effective option, U.K. researchers say

May 22, 2013 by Arezu Sarvestani

The latest update from Medtronic's (NYSE:MDT) ADVANCE registry of patients treated with the CoreValve transcatheter aortic valve implantation evaluated the technology from a cost perspective, with researchers reporting that CoreValve is worth the money for patients with severe aortic stenosis.

ALung pursues Chinese approval for Hemolung

May 22, 2013 by Sony Salzman

ALung Technologies said it's pursuing approval from Chinese regulatory authorities for its Hemolung respiratory assist system.

The Pittsburgh-based medical device company said it inked a deal with Curative Medical to seek approval for the Hemolung device from the China Food & Drug Administration.

EuroPCR: Medtronic's renal denervation looks good in the real world

May 21, 2013 by Arezu Sarvestani

Medical device industry giant Medtronic (NYSE:MDT) this week offered a 1st look at results from its global Symplicity registry of renal denervation patients, finding that treatment with the company's Symplicity system appears safe as well as effective in real-world patients.

Stentys enrolls 1st patient in U.S. stent trial

May 21, 2013 by Sony Salzman

Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.

The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.